Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

阿替唑单抗 医学 危险系数 内科学 肿瘤科 质子抑制剂泵 人口 癌症 膀胱癌 相伴的 化疗 随机对照试验 置信区间 免疫疗法 无容量 环境卫生
作者
Ashley M. Hopkins,Ganessan Kichenadasse,Christos S. Karapetis,Andrew Rowland,Michael J. Sorich
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (20): 5487-5493 被引量:77
标识
DOI:10.1158/1078-0432.ccr-20-1876
摘要

Emerging evidence indicates that gut microbiota dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). Proton pump inhibitors (PPI) are known to induce gut microbiota changes. However, little is known on the effects of PPIs on outcomes with ICI therapy, and it has not been explored in urothelial cancer treatment.Individual-participant data from the advanced urothelial cancer trials, IMvigor210 (single-arm atezolizumab trial, n = 429) and IMvigor211 (phase III randomized trial of atezolizumab vs. chemotherapy, n = 931) were pooled in a Cox proportional hazard analysis assessing the association between PPI use and overall survival (OS) and progression-free survival (PFS). PPI use was defined as any PPI administration between 30 days prior and 30 days after treatment initiation.Of the 1,360 participants, 471 (35%) received a PPI within the 60-day window. PPI use was associated with significantly worse OS [HR (95% confidence interval (CI)) = 1.52 (1.27-1.83), P < 0.001] and PFS [1.38 (1.18-1.62), P < 0.001] with atezolizumab, but not chemotherapy (P > 0.05). In the randomized cohort of IMvigor211, the OS treatment effect [HR (95% CI)] of atezolizumab versus chemotherapy was 1.04 (0.81-1.34) for PPI users, compared with 0.69 (0.56-0.84) for PPI nonusers (Pinteraction = 0.013). Similar associations were noted in the PD-L1 IC2/3 population.This study indicates PPI use is a negative prognostic marker in advanced urothelial carcinoma treated with ICI therapy, but not chemotherapy. Furthermore, the analysis suggests PPIs influence the magnitude of ICI efficacy, and this warrants further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宋宋完成签到,获得积分10
刚刚
星辰大海应助啊啊采纳,获得10
刚刚
田様应助啊啊采纳,获得10
1秒前
1234发布了新的文献求助10
2秒前
负负发布了新的文献求助10
3秒前
thz完成签到,获得积分20
4秒前
ferny完成签到,获得积分10
4秒前
coolru发布了新的文献求助50
5秒前
翟帅亚完成签到 ,获得积分10
6秒前
汉堡包应助啊啊采纳,获得10
6秒前
领导范儿应助啊啊采纳,获得10
6秒前
NexusExplorer应助啊啊采纳,获得10
6秒前
7秒前
CipherSage应助啊啊采纳,获得10
7秒前
完美世界应助啊啊采纳,获得10
7秒前
Hello应助啊啊采纳,获得10
7秒前
无花果应助啊啊采纳,获得10
7秒前
春樹暮雲完成签到 ,获得积分10
7秒前
斯文败类应助啊啊采纳,获得10
7秒前
小蘑菇应助啊啊采纳,获得10
7秒前
zhaxiao发布了新的文献求助10
7秒前
ferny发布了新的文献求助10
8秒前
Churchill87426完成签到,获得积分10
9秒前
9秒前
echo完成签到 ,获得积分10
10秒前
万能图书馆应助负负采纳,获得10
10秒前
sbw发布了新的文献求助10
10秒前
11秒前
12秒前
yaya发布了新的文献求助10
12秒前
1234完成签到,获得积分10
12秒前
thchiang完成签到 ,获得积分10
13秒前
面壁思过应助圈圈叉叉采纳,获得10
14秒前
CHB只争朝夕完成签到 ,获得积分10
14秒前
安超楷完成签到,获得积分10
14秒前
开放觅夏发布了新的文献求助30
15秒前
16秒前
19秒前
20秒前
开放觅夏完成签到,获得积分10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403